After adjusting for parameters such as gender, age, grade, and recurrence, CXCL13/CD163 coexpression was also regarded as an independent prognostic indicator of patient survival in astrocytoma (HR = 1.682, 95% CI: 1.032–2.740, p = 0.0368; Table 3). Here, CXCL13 is linked to astrocytoma (excluding glioblastoma).